Immunome, Inc. (IMNM) Financial Ratios
8 years of historical data (2018–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
3.06
+19% vs avg
5yr avg: 2.58
30Y Low1.6·High3.4
ROE
↑
-52.1%
↓+54% vs avg
5yr avg: -114.4%
30Y Low-195%·High-52%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
IMNM Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Immunome, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2.5B | $1.9B | $623M | $212M | $27M | $150M | $98M | — | — |
| Enterprise Value | $1.9B | $1.2B | $484M | $115M | $7M | $101M | $59M | — | — |
| P/E Ratio → | -9.13 | — | — | — | — | — | — | — | — |
| P/S Ratio | 361.68 | 270.32 | 68.88 | 15.15 | — | — | — | — | — |
| P/B Ratio | 3.06 | 2.96 | 3.44 | 1.77 | 1.61 | 3.10 | 2.37 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
IMNM EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 176.73 | 53.56 | 8.23 | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — |
IMNM Profitability
Margins and return-on-capital ratios measuring operating efficiency
Immunome, Inc. earns an operating margin of -3228.8%. Operating margins have compressed from -781.4% to -3228.8% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -52.1% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | 100.0% | 100.0% | — | — | — | — | — |
| Operating Margin | -3228.8% | -3228.8% | -3382.4% | -781.4% | — | — | — | — | — |
| Net Profit Margin | -3060.0% | -3060.0% | -3240.4% | -761.9% | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | -52.1% | -52.1% | -194.6% | -156.5% | -113.8% | -55.2% | -624.2% | — | — |
| ROA | -46.0% | -46.0% | -150.7% | -123.8% | -90.0% | -48.2% | -71.9% | -221.9% | -176.4% |
| ROIC | -1228.6% | -1228.6% | -700.3% | -843.7% | — | -2580.6% | — | — | — |
| ROCE | -54.4% | -54.4% | -195.6% | -152.7% | -113.7% | -56.2% | -54.6% | -329.4% | -268.2% |
IMNM Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $653M exceeds total debt of $4M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.03 | 0.01 | 0.02 | 0.01 | 0.01 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.02 | -0.76 | -0.81 | -1.20 | -1.02 | -0.95 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | -7380.20 | -2520.40 | -322.66 | -97.62 | -54.91 |
Net cash position: cash ($653M) exceeds total debt ($4M)
IMNM Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Immunome, Inc.'s current ratio of 14.69x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 6.63x to 14.69x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 14.69 | 14.69 | 4.08 | 6.63 | 3.09 | 5.82 | 14.12 | 1.88 | 1.35 |
| Quick Ratio | 14.69 | 14.69 | 4.08 | 6.63 | 3.09 | 5.82 | 14.12 | 1.88 | 1.35 |
| Cash Ratio | 14.53 | 14.53 | 4.00 | 6.33 | 2.77 | 5.06 | 13.09 | 1.53 | 1.03 |
| Asset Turnover | — | 0.01 | 0.04 | 0.09 | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | 7.53 | — | — | — | — | — |
IMNM Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Immunome, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $87M | $59M | $20M | $12M | $12M | $10M | $6M | $1M |
Peer Comparison
Compare IMNM with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 IMNMYou | $3B | -9.1 | — | — | — | -3228.8% | -52.1% | -1228.6% | — |
 IMVT | $6B | -10.0 | — | — | — | — | -62.5% | — | — |
 RCUS | $2B | -7.5 | — | — | 96.0% | -156.3% | -63.3% | -64.1% | — |
 AGEN | $132M | -1102.9 | — | — | 90.3% | -18.0% | — | — | — |
 FATE | $280M | -2.1 | — | — | — | -2222.4% | -51.8% | -36.5% | — |
 MGNX | $186M | -2.5 | — | — | — | -48.7% | -86.9% | -1879.3% | — |
 NKTR | $2B | -8.6 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 XNCR | $903M | -9.9 | — | — | 91.6% | -141.4% | -14.0% | -16.3% | — |
 ALKS | $6B | 24.8 | 17.3 | 12.3 | 86.7% | 17.2% | 14.7% | 18.9% | 0.2 |
 AGIO | $2B | -3.9 | — | — | 78.7% | -873.9% | -30.2% | -26.3% | — |
 KYMR | $7B | -22.9 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 8 years · Updated daily
See IMNM's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs IMNM Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare IMNM vs IMVT
Side-by-side business, growth, and profitability comparison vs Immunovant, Inc..
Start ComparisonIMNM — Frequently Asked Questions
Quick answers to the most common questions about buying IMNM stock.
What is Immunome, Inc.'s P/E ratio?
Immunome, Inc.'s current P/E ratio is -9.1x. This places it at the 50th percentile of its historical range.
What is Immunome, Inc.'s ROE?
Immunome, Inc.'s return on equity (ROE) is -52.1%. The historical average is -114.4%.
Is IMNM stock overvalued?
Based on historical data, Immunome, Inc. is trading at a P/E of -9.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Immunome, Inc.'s profit margins?
Immunome, Inc. has -3228.8% operating margin.